SERACARE LIFE SCIENCES INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2011-11-17: Form 8-K; Period of report 2011-11-17; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2011-08-01: Form 8-K; Period of report 2011-08-01; Description 8.01 Other Events; Details 8.01.
- 2011-07-26: Form 8-K; Period of report 2011-07-25; Description 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 2.02.
- 2011-06-23: Form 8-K; Period of report 2011-06-23; Description 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2011-11-17 | 8-K | 2011-11-17 | 2.02 Results of Operations and Financial Condition | 2.02 On November 17, 2011, we issued a press release announcing our financial results for the quarter and fiscal year ended September 30, 2011. | v241025_8k.htm |
| 2011-08-01 | 8-K | 2011-08-01 | 8.01 Other Events | 8.01 On August 1, 2011, SeraCare Life Sciences, Inc. (the “Company”) announced that its Board of Directors has initiated a process to explore and evaluate potential strategic alternatives for the Company to enhance shareholder value, which may include a sale or other transaction. | v230370_8k.htm |
| 2011-07-26 | 8-K | 2011-07-25 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 On July 26, 2011, we issued a press release announcing our financial results for the quarter ended June 30, 2011. 5.02 On July 25, 2011, the employment of Susan L.N. Vogt as our President and Chief Executive Officer was terminated without cause. | v229717_8k.htm |
| 2011-06-23 | 8-K | 2011-06-23 | 7.01 Regulation FD Disclosure | 7.01 On June 23, 2011, SeraCare Life Sciences, Inc., (the "Company") announced the receipt of an unsolicited offer from MSMB Capital proposing to purchase all of the outstanding shares of the Company for $4.25 per share. | htm_42141.htm |
| 2011-05-12 | 8-K | 2011-05-10 | 2.02 Results of Operations and Financial Condition; 5.07 Submission of Matters to a Vote of Security Holders | 2.02 On May 12, 2011, we issued a press release announcing our financial results for the quarter ended March 31, 2011. 5.07 On May 10, 2011, we held our 2011 Annual Meeting of Stockholders, at which two proposals were submitted to, and approved by, our stockholders. | v222080_8k.htm |
| 2011-05-02 | 8-K | 2011-04-27 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 The information set forth in the press release issued by the Company, dated May 2, 2011, and attached hereto as Exhibit 99.1 is incorporated herein by reference. | v220429_8k.htm |
| 2011-03-04 | 8-K | 2011-03-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 At a meeting of the Nominating and Corporate Governance Committee of our Board of Directors held on March 2, 2011, each of Samuel D. Anderson and Eugene I. Davis notified us of his decision not to stand for re-election to the Board of Directors at our 2011 annual meeting of stockholders in order to make room for the election of new directors. 8.01 On March 3, 2011, our Board of Directors selected May 10, 2011 as the date of our 2011 annual meeting of stockholders. | v213668_8k.htm |
| 2011-02-11 | 8-K | 2011-02-11 | 2.02 Results of Operations and Financial Condition | 2.02 On February 11, 2011, we issued a press release announcing our financial results for the quarter ended December 31, 2010. | v210839_8k.htm |
| 2011-01-13 | 8-K | 2010-12-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 31, 2010, we entered into a severance agreement with William J. Smutny, our former Vice President, Sales and Marketing, relating to the termination of Mr. Smutny’s employment. | v207980_8k.htm |
| 2011-01-12 | 8-K | 2011-01-11 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On January 11, 2011, we engaged BDO USA, LLP as our independent registered public accounting firm after a thorough selection process, which included meeting with, and reviewing proposals from, several candidates. | v207623_8k.htm |
| 2011-01-12 | 8-K | 2011-01-11 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On January 11, 2011, we engaged BDO USA, LLP as our independent registered public accounting firm after a thorough selection process, which included meeting with, and reviewing proposals from, several candidates. | v207623_8k.htm |
| 2011-01-06 | 8-K | 2010-12-30 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.03 On December 30, 2010, SeraCare Life Sciences, Inc. (the “Company”) entered into a secured Loan Agreement (the “Loan Agreement”) by and among the Company, as borrower, the lenders from time to time party thereto (which are initially Middlesex Savings Bank and Commerce Bank and Trust Company), and Middlesex Savings Bank, as letter of credit issuer and as administrative agent for the lenders (the “Administrative Agent”). 8.01 The information set forth in the press release issued by the Company, dated January 6, 2011, and attached hereto as Exhibit 99.1 is incorporated herein by reference. | v207435_8k.htm |